Current Treatment Options in Allergy

, Volume 5, Issue 1, pp 140–153 | Cite as

Allergic Contact Dermatitis: Therapeutic Management

  • I. Poveda-Montoyo
  • P. J. Álvarez-Chinchilla
  • J. F. Silvestre
Contact Dermatitis (M Gonçalo, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Contact Dermatitis


Purpose of Review

Allergic contact dermatitis (ACD) is a common condition and may entail negative impacts on people’s quality of life along with a substantial economic burden. Appropriately managing it through patient education, allergen avoidance, and symptomatic treatment is crucial for its resolution. Our review aims to establish a practical approach to ACD management, based on a comprehensive discussion of available therapeutic options for ACD, a review of the latest findings in this field, and personal insights from our clinical practice experience.

Recent Findings

Topical treatments constitute the first-line therapy for ACD. Randomized clinical trials have shown topical corticosteroids to improve clinical and nonclinical outcomes, while tacrolimus has proven effective and safe. Evidence is lacking for oral corticosteroids in ACD sufferers, so recommendations for its use are primarily based on results obtained in dermatitis of other etiologies. In contrast, some studies have assessed azathioprine and phototherapy for ACD.


Patient education and allergen avoidance are paramount for managing ACD. However, individualized symptomatic treatment is warranted in several clinical situations. Although these treatments are widely used in clinical practice, few studies support their use for ACD. Further research is needed.


Allergen avoidance Allergic contact dermatitis Allergic dermatitis Therapeutic management Treatment Therapy Management 


Compliance with Ethical Standards

Conflict of Interest

Inés Poveda-Montoyo declares that he has no conflict of interest. P. J. Álvarez-Chinchilla declares that he has no conflict of interest. J. F. Silvestre declares that he has no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Jacob SE, Castanedo-Tardan MP. Pharmacotherapy for allergic contact dermatitis. Expert Opin Pharmacother. 2007;8:2757–74. A comprehensive review of the symptomatic and immunosuppressive therapy available in allergic contact dermatitis.CrossRefPubMedGoogle Scholar
  2. 2.
    Diepgen TL, Ofenloch RF, Bruze M, Bertuccio P, Cazzaniga S, Coenraads PJ, et al. Prevalence of contact allergy in the general population in different European regions. Br J Dermatol. 2016;174:319–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Mowad CM, Anderson B, Scheinman P, Pootongkam S, Nedorost S, Brod B. Allergic contact dermatitis. J Am Acad Dermatol. 2016;74:1043–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Mark BJ, Slavin RG. Allergic contact dermatitis. Med Clin N Am. 2006;90:169–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Behrens V, Seligman P, Cameron L, Mathias CGT, Fine L. The prevalence of back pain, hand discomfort, and dermatitis in the US working population. Am J Public Health. 1998;84:1780–5.CrossRefGoogle Scholar
  6. 6.
    Belsito DV. The diagnostic evaluation, treatment, and prevention of allergic contact dermatitis in the new millennium. J Allergy Clin Immunol. 2000;105:409–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Rundle CW, Bergman D, Goldenberg A, Jacob SE. Contact dermatitis considerations in atopic dermatitis. Clin Dermatol. 2017;35:367–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF. Allergic and irritant contact dermatitis. Eur J Dermatol. 2009;19:325–32.PubMedGoogle Scholar
  9. 9.
    •• Johnston GA, Exton LS, Mohd Mustapa MF, Slack JA, Coulson IH, English JS, et al. British Association of Dermatologists’ guidelines for the management of contact dermatitis. Br J Dermatol. 2017;176:317–29. Guidelines providing up-to-date and evidence-based recommendations for the management of contact dermatitis.CrossRefPubMedGoogle Scholar
  10. 10.
    Scalf LA, Genebriera J, Davis MDP, Farmer SA, Yiannias JA. Patients’s perceptions of the usefulness and outcome of patch testing. J Am Acad Dermatol. 2007;56:928–32.CrossRefPubMedGoogle Scholar
  11. 11.
    • Mowad CM. Contact dermatitis. Practice gaps and challenges. Dermatol Clin. 2016;34:263–7. Elaborate manuscript discussing the most frequent gaps and challenges in contact dermatitis.CrossRefPubMedGoogle Scholar
  12. 12.
    • Bernstein DI. Contact dermatitis for the practicing allergist. J Allergy Clin Immunol Pract. 2015;3:652–8. Current overview of the diagnosis and treatment of contact dermatitis.CrossRefPubMedGoogle Scholar
  13. 13.
    González de Domingo MA, Conde-Salazar Gomez L: Tratamiento de las dermatosis laborales. In: Conde-Salazar L, Ancona-Alayón A editors. Dermatología profesional. Aula Médica;2004.Google Scholar
  14. 14.
    Levin CY, Maibach HI. Do cool water or physiologic saline compresses enhance resolution of experimentally-induced irritant contact dermatitis? Contact Dermatitis. 2001;45:146–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Brown T. Strategies for prevention: Occupational contact dermatitis. Occup Med Oxf Engl. 2004;54:450–7.CrossRefGoogle Scholar
  16. 16.
    Ramsing DW, Agner T. Preventive and therapeutic effects of a moisturizer. An experimental study of human skin. Acta Derm Venereol. 1997;77:335–7.PubMedGoogle Scholar
  17. 17.
    Menné T, Johansen JD, Sommerlund M, Veien NK, Danish Contact Dermatitis Group. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis. 2011;65:3–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Diepgen TL, Elsner P, Schliemann S, Fartasch M, Köllner A, Skudlik C, et al. Guideline on the management of hand eczema ICD-10 Code: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges J Ger SocDermatol JDDG. 2009;7(Suppl 3):S1–16.Google Scholar
  19. 19.
    •• De León FJ, Berbegal L, Silvestre JF. Abordaje terapéutico en el eczema crónico de manos. Actas Dermosifilogr. 2015;106:533–44. A thorough review of the management of chronic hand eczema, including the allergic etiology. Practical recommendations about prevention and treatment are provided in this manuscript.CrossRefGoogle Scholar
  20. 20.
    Hachem JP, De Paepe K, Vanpee E, Kaufman L, Rogiers V, Roseeuw D. Combination therapy improves the recovery of the skin barrier function: an experimental model using a contact allergy patch test combined with TEWL measurements. Dermatology. 2001;202:314–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Wigger-Alberti W, Maraffio B, Wernli M, Elsner P. Self applications of a protective cream. Pitfalls of occupational skin protection. Arch Dermatol. 1997;133:861–4.CrossRefPubMedGoogle Scholar
  22. 22.
    •• Brasch J, Becker D, Aberer W, Bircher A, Kränke B, Jung K, et al. Guideline contact dermatitis. S1-Guideline of the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG. Allergo J Int. 2014;23:126–38. Guidelines describing the diagnosis and therapeutic and interventional approaches of contact dermatitis based on the latest scientific evidence.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bourke J, Coulson I, English J, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of contact dermatitis: an update. Br J Dermatol. 2009;160:946–54.CrossRefPubMedGoogle Scholar
  24. 24.
    Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatol Ther. 2004;17:334–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest. 2007;117:1381–90.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Saary J, Qureshi R, Palda V, DeKoven J, Pratt M, Skotnicki-Grant S, et al. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol. 2005;53:845–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Hachem JP, De Paepe K, Vanpee E, Bogaerts M, Kaufman L, Rogiers V, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol. 2002;27:47–50.CrossRefPubMedGoogle Scholar
  28. 28.
    Parneix-Spake A, Goustas P, Green R. Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis. J Dermatol Treat. 2001;12:191–7.CrossRefGoogle Scholar
  29. 29.
    Quielle-Roussel C, Duteil L, Padilla JM, Poncet M, Czernielewski J. Objective assessment of topical anti-inflammatory drug activity on experimentally induced nickel contact dermatitis: comparison between visual scoring, colorimetry, laser Doppler velocimetry and transepidermal water loss. Skin Pharmacol. 1990;3:248–55.CrossRefGoogle Scholar
  30. 30.
    Vernon HJ, Olsen EA. A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis. J Am Acad Dermatol. 1990;23:829–32.CrossRefPubMedGoogle Scholar
  31. 31.
    Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. American Academy of Dermatology. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol. 1996;35:615–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol. 2001;45:736–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Belsito DV, Wilson DC, Warshaw E, Fowler J, Ehrlich A, Anderson B, et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol. 2006;55:40–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol. 2003;49:477–82.CrossRefPubMedGoogle Scholar
  35. 35.
    Alomar A, Puig L, Gallardo CM, Valenzuela N. Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis. 2003;49:185–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Katsarou A, Makris M, Papagiannaki K, Lagogianni E, Tagka A, Kalogeromitros D. Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol. 2012;22:192–6. Scholar
  37. 37.
    Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis. J Eur Acad Dermatol Venerol. 2009;23:382–7. Scholar
  38. 38.
    Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003;17:500.Google Scholar
  39. 39.
    Amrol D, Keitel D, Hagaman D, Murray J. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol. 2003;91:563–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Anveden I, Lindberg M, Andersen KE, Bruze M, Issakson M, Liden C, et al. Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis. 2004;50:298–303.CrossRefPubMedGoogle Scholar
  41. 41.
    Verma KK, Mahesh R, Bhari N, Pandey RM. Effect of betamethasone on patch test reactivity in patients with parthenium dermatitis. Contact Dermatitis. 2016;75:193–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Rietschel RL, Fowler JF. Fisher’s contact dermatitis. Lippincott Williams Wilkins. Philadelphia. 2001:715–21.Google Scholar
  43. 43.
    Sharma VK, Chakrabarti A, Mahajan V. Azathioprine in the treatment of parthenium dermatitis. Int J Dermatol. 1998;37:299.CrossRefPubMedGoogle Scholar
  44. 44.
    Verma KK, Bansal A, Sethuraman G. Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol. 2006;72:24–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Quéméneur L, Michallet MC, Ferraro-Peyret C, Saint-Mézard P, Benetière J, Ducluzeau MT, et al. Immunosuppressive antimetabolites inhibit induction of contact hypersensitivity while lymphoablative drugs also prevent its expression. Eur J Dermatol. 2003;13:540–7.PubMedGoogle Scholar
  46. 46.
    Schindler M, Drozdenko G, Kühl AA, Worm M. Immunomodulation in patients with chronic hand eczema treated with oral alitretinoin. Int Arch Allergy Immunol. 2014;165:18–26.CrossRefPubMedGoogle Scholar
  47. 47.
    Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: Results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808–17.CrossRefPubMedGoogle Scholar
  48. 48.
    Thestrup-Pedersen K, Andersen KE, Menné T, Veien NK. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. Acta Derm Venereol. 2001;81:353–5.CrossRefPubMedGoogle Scholar
  49. 49.
    Capella GL, Fracchiolla C, Frigerio E, Altomare G. A controlled study of comparative efficacy of oral retinoids and topical betamethasone/salicylic acid for chronic hyperkeratotic palmoplantar dermatitis. J Dermatol Treat. 2004;15:88–93.CrossRefGoogle Scholar
  50. 50.
    Piguet PF, Grau GE, Hauser C, Vassalli P. TNF is a critical mediator in hapten-induced irritant and contact hypersensitivity reactions. J Exp Med. 1991:173–673-9.Google Scholar
  51. 51.
    Rosen K, Mobacken H, Swanbeck G. Chronic eczematous dermatitis of the hands. A comparison of PUVA and UVB treatment. Acta Derm Venereol. 1987;67:48–54.PubMedGoogle Scholar
  52. 52.
    Dooms-Goossens A, Andersen KE, Brandao FM, Bruynzeel D, Burrows D, Camarasa J, et al. Corticosteroid contact allergy: An EECDRG multicentre study. Contact Dermatitis. 1996;35:40–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Jacob SE, Steele T. Corticosteroid classes: A quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol. 2006;54:723–7.CrossRefPubMedGoogle Scholar
  54. 54.
    • Berbegal L, DeLeón FJ, Silvestre JF. Hypersensitivity reactions to corticosteroids. Actas Dermosifiliogr. 2015;106:816–22. Useful manuscript detailing patients’ profiles and management of corticosteroids allergy, a potential complication present in allergic contact dermatitis.CrossRefPubMedGoogle Scholar
  55. 55.
    Baeck M, Chamelle JA, Goossens A, Nicolas JF, Terreux R. Corticosteroid cross-reactivity: Clinical and molecular modelling tools. Allergy. 2011;66:1367–74.CrossRefPubMedGoogle Scholar
  56. 56.
    Baeck M, Goossens A. Immediate, delayed allergic hypersensitivity to corticosteroids: Practical guidelines. Contact Dermatitis. 2011;66:38–45.CrossRefPubMedGoogle Scholar
  57. 57.
    Baeck M, Chemelle JA, Rasse C, Terreux R, Goossens A. C(16)-methyl corticosteroids are far less allergenic than the non-methylated molecules. Contact Dermatitis. 2011;64:305–12.CrossRefPubMedGoogle Scholar
  58. 58.
    • DeKoven JG, Warshaw EM, Belsito DV, Sasseville D, Maibach HI, Taylor JS, et al. North American Contact Dermatitis Group Patch Test Results 2013–2014. Dermatitis. 2017;28:33–46. Study showing the latest patch testing results in North America. This manuscript identifies the most prevalent allergens and also presents the rate of occupational contact dermatitis.CrossRefPubMedGoogle Scholar
  59. 59.
    • Pesonen M, Jolanki R, Larese Filon F, Wilkinson M, Kręcisz B, Kieć-Świerczyńska M, et al. Patch test results of the European baseline series among patients with occupational contact dermatitis across Europe - analyses of the European Surveillance System on Contact Allergy network, 2002–2010. Contact Dermatitis. 2015;72:154–63. Study presenting the latest results of prevalence and most frequent allergens in occupational allergic contact dermatitis in European population.CrossRefPubMedGoogle Scholar
  60. 60.
    Smedley J, on behalf of the OHCEU and BOHRF Dermatitis guideline development groups. Concise guidance: diagnosis, management and prevention of occupational contact dermatitis. Clin Med. 2010;10:487–90.CrossRefGoogle Scholar
  61. 61.
    Weisshaar E, Skudlik C, Scheidt R, Matterne U, Wulfhorst B, Schönfeld M, et al. Multicentre study “rehabilitation of occupational skin diseases -optimization and quality assurance of inpatient management (ROQ)”-Results from 12-month follow-up. Contact Dermatitis. 2013;68:169–74.CrossRefPubMedGoogle Scholar
  62. 62.
    Pryce DW, Irvine D, English JS, Rycroft RJ. Soluble oil dermatitis: a follow-up study. Contact Dermatitis. 1989;21:28–38.CrossRefPubMedGoogle Scholar
  63. 63.
    •Uter W, Amario-Hita JC, Balato A, Ballmer-Weber B, Bauer A, Belloni-Fortina A, et al. European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14. J Eur Acad Dermatol Venereol 2017;31:1516–1525. A recent study presenting the most prevalent allergens after patch testing in European population. Google Scholar
  64. 64.
    Arribas MP, Soro P, Silvestre JF. Allergic Contact Dermatitis to Fragrances. Part 1. Actas Dermosifiliogr. 2012;103:874–9.CrossRefGoogle Scholar
  65. 65.
    Arribas MP, Soro P, Silvestre JF. Allergic contact dermatitis to fragrances: part 2. Actas Dermosifiliogr. 2013;104:29–37.CrossRefPubMedGoogle Scholar
  66. 66.
    Nelson SA, Yiannias JA. Relevance and avoidance of skin-care product allergens: pearls and pitfalls. Dermatol Clin. 2009;27:329–36.CrossRefPubMedGoogle Scholar
  67. 67.
    Leiva-Salinas M, Francés L, Silvestre JF. Update on allergic contact dermatitis due to methylchloroisothiazolinone/methylisothiazolinone and methylisohiazolinone. Actas Dermosifiliogr. 2014;105:840–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Castanedo-Tardan MP, Zug KA. Patterns of cosmetic contact allergy. Dermatol Clin. 2009;27:265–80.CrossRefPubMedGoogle Scholar
  69. 69.
    • Consuegra-Romero G, Castro-Gutiérrez B, González-López MA. Photoallergic contact dermatitis. Eur J Intern Med. 2017;38:e4–5. Interesting case report and review of photoallergic contact dermatitis, a special type of allergic contact dermatitis that should be taken into accountCrossRefPubMedGoogle Scholar
  70. 70.
    Kerr A, Ferguson J. Photoallergic contact dermatitis. Photodermatol Photoimmunol Photomed. 2010;26:56–65.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • I. Poveda-Montoyo
    • 1
  • P. J. Álvarez-Chinchilla
    • 1
  • J. F. Silvestre
    • 1
  1. 1.Dermatology Department, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL)Hospital General Universitario de AlicanteAlicanteSpain

Personalised recommendations